Modality
Radioligand
MOA
EZH2i
Target
IL-13
Pathway
Innate Imm
NMOSDADPKDMelanoma
Development Pipeline
Preclinical
~Jan 2017
→ ~Apr 2018
Phase 1
Jul 2018
→ May 2027
Phase 1Current
NCT07818321
760 pts·Melanoma
2020-11→2027-05·Terminated
NCT07625218
232 pts·NMOSD
2018-07→2026-09·Completed
992 total pts2 indications
Phase 2
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (2)
2026-09-015mo awayInterim· NMOSD
2027-05-011.1y awayInterim· Melanoma
Trial Timeline
Q3Q42019Q2Q3Q42020Q2Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3
P1
Complet…
P1
Termina…
Catalysts
Interim
2026-09-01 · 5mo away
NMOSD
Interim
2027-05-01 · 1.1y away
Melanoma
CompletedTerminated|StartCompletionToday
Trials (2)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT07818321 | Phase 1 | Melanoma | Terminated | 760 | LiverFat |
| NCT07625218 | Phase 1 | NMOSD | Completed | 232 | MRD |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| Lisonaritide | Eli Lilly | Phase 3 | IL-13 | |
| Adagrazumab | Novartis | Phase 2/3 | Cl18.2 | |
| Ribotuximab | Merck & Co | Phase 2 | GPRC5D | |
| Sovarapivir | AbbVie | Phase 2/3 | IL-13 | |
| Ceviderotide | Novo Nordisk | Preclinical | IL-13 | |
| NVO-9615 | Novo Nordisk | Phase 2/3 | PRMT5 | |
| DSN-3066 | Daiichi Sankyo | Phase 3 | IL-13 | |
| MRN-7601 | Moderna | Phase 2 | IL-13 | |
| Polalucimab | Jazz Pharma | Preclinical | PLK4 | |
| ASN-7038 | Ascendis Pharma | Phase 3 | VEGF |